Beverly Hills MD has introduced a new skincare product called ProRetinol Age Rewind x3, which is being marketed as the first cream to combine exosomes with a triple-retinoid blend. Developed by plastic surgeons Dr. John Layke and Dr. Payman Danielpour, this innovation aims to address a common consumer frustration — the irritation, dryness, and peeling often associated with traditional retinol use.
What sets Beverly Hills MD's ProRetinol Age Rewind x3 formula apart is its slow-release mechanism, which is designed to deliver anti-aging benefits such as reduced fine lines, improved firmness, and more even skin tone without compromising the skin’s natural barrier.
All in all, the ProRetinol Age Rewind x3 product by Beverly Hills MD is positioned to offer a gentler alternative for those who have previously abandoned retinol due to sensitivity, while still incorporating advanced ingredients like peptides, antioxidants, and biomimetic exosomes that support deeper rejuvenation.
Image Credit: Beverly Hills MD
Key Themes Behind This Trend
- Biomimetic Exosome Delivery
- The integration of biomimetic exosomes with topical actives is enabling deeper cellular signaling and targeted tissue repair that could redefine efficacy benchmarks for noninvasive rejuvenation.
- Triple-retinoid Slow-release Formulations
- A multi-retinoid, slow-release approach is reducing peak irritation while maintaining sustained bioactivity, creating potential for higher-strength regimens tolerated by sensitive skin types.
- Barrier-friendly Anti-aging Solutions
- Formulations prioritizing barrier preservation alongside potent actives are shifting consumer expectations toward products that deliver clinical results without compromising skin integrity.
Where This Applies
- Dermocosmetics
- Advanced formulations that combine pharmaceutical-grade actives with biotechnologies are opening pathways for clinically positioned consumer products that bridge cosmeceutical and medical claims.
- Medical Aesthetics
- Clinician-developed topical technologies are extending procedural outcomes into at-home maintenance regimes, creating avenues for bundled in-clinic and at-home treatment models.
- Ingredient Manufacturing
- Demand for stable, scalable exosome and controlled-release retinoid intermediates is encouraging innovation in biofabrication and supply-chain specialization for novel delivery systems.
